Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Press Release
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royalties Glaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseases Nicox focused on continued Phase 3 development of lead drug-candidate, NCX 470 September 23^rd, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has entered into an exclusive research and license option agreement with Glaukos Corporation for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. Glaukos is a US ophthalmic pharmaceutical and medical device company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. “Glaukos possesses expertise in the treatment of ophthalmic disorders and has unique drug delivery capabilities which could optimize NCX 1728 for uses including reduction of intraocular pressure, neuroprotection and as a potential treatment for retinal diseases. Glaukos is therefore an ideal partner to accelerate the research and development of this unique compound and deliver on its therapeutic potential. We look forward to working with Glaukos to evaluate the use of this novel molecule in multiple different indications.” said Doug Hubatsch, Chief Scientific Officer of Nicox. Under the terms of the agreement, Glaukos will fund the evaluation of NCX 1728 in a preclinical research program agreed between Nicox and Glaukos. The program will explore indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases, with the activities being overseen by a Joint Steering Committee. Glaukos has an option to license NCX 1728 on an exclusive global basis for development in these ophthalmic conditions, which can be exercised within certain specified periods, the first of which is in 12 months. The pre-agreed terms, which would initiate upon signature of a license agreement following Glaukos’s exercise of its option to license, include standard economic provisions for a license agreement of this nature. For further information on Glaukos, please go to www.glaukos.com. About NCX 1728 NCX 1728, an NO-donating PDE5 inhibitor, is the lead compound of a new class of NO-donating molecules in which the NO-mediated effects are enhanced and prolonged by concomitant PDE5 inhibition in the same molecule. PDE5 inhibition has been previously shown to enhance the efficacy and prolong the duration of NO-mediated effects.
About Nicox
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com
Analyst coverage
H.C. Wainwright & Co Yi Chen New York, U.S.
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts
Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com	Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.com
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” which is available on Nicox’s website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.
Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00